US biotech firms Regeneron Pharmaceuticals (Nasdaq: REGN) and Inovio Pharmaceutical (Nasdaq: INO) have joined forces for a Phase I/IIa immuno-oncology trial.
The study will be conducted by Inovio in patients with newly-diagnosed glioblastoma multiforme (GBM) and will evaluate Regeneron's PD-1 inhibitor, REGN2810, in combination with Inovio's INO-5401 T cell activating immunotherapy encoding multiple antigens and INO-9012, an immune activator encoding interleukin (IL)-12.
REGN2810 is also being developed under a multi-billion-dollar collaboration with French pharma major Sanofi (Euronext: SAN) and is currently in a Phase II advanced cutaneous squamous cell carcinoma trial.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze